PatternsRadar
Sign in

CONCORDBIOConcord Biotech Limited

NSE
548.20INR-8.20 (-1.47%)Close · 20 Nov 2026
27 Oct 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹11,470 CrMarket cap
40.6P/E (TTM)
57.4%Delivery

Filings & corporate actions

14 results filed
CSV
Next results · Q3 FY27
Expected 9 Feb 2027 – 14 Feb 2027
Estimate: filed 40–45 days after quarter end, last 3 times
Dividend
₹7.55 per share · last 24 Jul 2026
2026
  • 12 NovshareholdingShareholding · 5 Nov 2026+0.8%NSE
  • 4 NovbonusBonus issue · factor 2.00 · record 4 Nov 2026+6.8%
  • 27 OctresultsResults · Q2 FY27 · consolidated and standalone-7.8%NSE
  • 17 OctshareholdingShareholding · 30 Sept 2026-4.0%NSE
  • 31 JulresultsResults · Q1 FY27 · consolidated and standalone-0.4%NSE
  • 24 JuldividendDividend · ₹7.55 per share-1.6%
  • 18 JulshareholdingShareholding · 30 Jun 2026-0.6%NSE
  • 29 MayresultsResults · Q4 FY26 · consolidated and standalone+1.0%NSE
  • 18 AprshareholdingShareholding · 31 Mar 2026-1.4%NSE
  • 11 FebresultsResults · Q3 FY26 · consolidated and standalone-1.3%NSE
  • 21 JanshareholdingShareholding · 31 Dec 2025-2.1%NSE

Reaction to results · all yearsrose on day 0 in 5 of 14 CSV

QuarterFiledDay 0+5D+20DRel vol
Q2 FY2727 Oct 2026-7.8%-4.7%—4.0×
Q1 FY2731 Jul 2026-0.4%-0.1%+1.8%3.2×
Q4 FY2629 May 2026+1.0%+13.8%+21.8%1.7×
Q3 FY2611 Feb 2026-1.3%-10.2%-5.0%0.8×
Q2 FY2613 Nov 2025+2.8%-2.1%-6.1%2.0×
Q1 FY268 Aug 2025+0.4%+3.1%+4.5%3.3×
Q4 FY2529 May 2025+4.9%+15.6%+9.4%5.9×
Q3 FY2514 Feb 2025-19.9%-21.9%-21.8%8.4×
Q2 FY2512 Nov 2024-1.1%+5.7%+13.8%0.5×
Q1 FY259 Aug 2024-2.0%+3.6%+17.0%2.1×
Q4 FY2424 May 2024-0.5%+0.3%+4.3%1.4×
Q3 FY249 Feb 2024-1.2%-0.8%+3.9%7.0×
Q2 FY249 Nov 2023+4.0%-1.4%-0.6%6.0×
Q1 FY246 Sept 2023-2.2%-0.2%+13.8%—
Average-1.7%+0.1%+4.4%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q2 FY27

Revenue YoY+25.1%
Profit YoY+11.1%
Interest cost YoY-24.2%
Revenue QoQ+20.0%
Profit QoQ+20.7%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+3.8%—————
Profit-7.2%—————

Key data

Open551.00
Day range546.10 – 558.00
52-week range493.50 – 807.50
From 52w high-32.1%
RSI (14)34.1
ATR (14)27.48
Volume1.29L
Avg volume (20D)3.84L
Rel volume0.34×
Volatility (1Y)43.6%
Turnover₹7.1Cr
Traded value (NSE)₹7.1Cr
VWAP550.11
SMA 50 / 200664.43 / 630.83
Price band20%

Delivery percentage

Latest · 20 Nov 202657.4%
20-day avg44.5%
1-year avg46.1%
Percentile (own history)78th
Range4.2–88.7%
Sessions809

Over the last 20 sessions CONCORDBIO settled 44.5% of its traded quantity, which is ordinary for an NSE equity. That is in line with its own one-year average of 46.1%. The latest session ranks higher than 78% of the 809 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

Dividends, deals & holders

Dividend yield0.69%
Dividend, trailing 12M₹3.78
Paid every year for2 yr
Shareholders91.3K · +3.4% QoQ
Net bulk deals, 30D0.00%
Block deals, 30D₹0
Last bulk buy268 days ago

Performance returns

1D1W1M3M6M1Y
Price-1.47%-7.71%-13.72%-30.46%-2.39%-26.87%

Valuation

Market cap₹11,470 Cr
Market cap (NSE)₹11,470 Cr
Free-float cap₹6,413 Cr
P/E (TTM)40.6
P/E (NSE)41.7
EPS (TTM)13.50
P/B5.5
Net margin (TTM)24.1%
Other income / PBT12.9%
ROE14.5%
Debt / equity0.00
Shares outstanding20.92Cr
Listed18 Aug 2023

Ownership

Promoter44.09%
Promoter Δ QoQ0.00 pp
Public55.91%
FII7.34%
DII11.01%
Pledged0.00%

Quarterly results · consolidated

Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue (₹ Cr)277.8326.1257.5309.1
YoY chg+13.7%-24.1%+26.2%+25.1%
Net profit (₹ Cr)63.688.557.769.6
YoY chg-16.2%-37.0%+31.0%+10.3%
Net margin22.9%27.1%22.4%22.5%
EPS3.044.232.763.33

Shareholding over time

By quarter

5 Nov 2026 · promoter 44.09% · public 55.91%
30 Sept 2023: promoter 44.08%31 Dec 2023: promoter 44.08%31 Mar 2024: promoter 44.08%30 Jun 2024: promoter 44.08%30 Sept 2024: promoter 44.08%31 Dec 2024: promoter 44.08%31 Mar 2025: promoter 44.08%30 Jun 2025: promoter 44.08%30 Sept 2025: promoter 44.08%31 Dec 2025: promoter 44.08%31 Mar 2026: promoter 44.08%30 Jun 2026: promoter 44.08%30 Sept 2026: promoter 44.09%5 Nov 2026: promoter 44.09%
2023-092026-11
  • Promoter
  • Public and others
Promoter
44.09%
Public
55.91%
Promoter change
0.00 pp
Filed
12 Nov 2026
FII
7.34%
DII
11.01%
Promoter pledged
0.00%

Who the public is

Mutual funds
5.85%

+0.01 pp QoQ

Insurance
4.28%

+0.02 pp QoQ

FPI
7.33%

+0.05 pp QoQ

Retail ≤ ₹2L
6.53%

-1.08 pp QoQ

HNI > ₹2L
2.25%

+1.05 pp QoQ

NRI
2.32%

+1.44 pp QoQ

Bodies corporate
1.76%

-0.51 pp QoQ

Shareholders
91,337

+3.4% QoQ

Major holders

As of 5 Nov 2026
HolderTypeHolding
SUDHIR KUMAR VAIDPromoter · Individual28.84%
MANJU VAIDPromoter · Individual9.55%
Aryavir Jhunjhunwala Discretionary TrustOther8.03%
Aryaman Jhunjhunwala Discretionary TrustOther8.03%
Nishtha JhunjhunwalaDiscretionary TrustOther8.03%
Sudman Consultants LlpPromoter · Corporate4.54%
DSP HEALTHCARE FUNDMutual fund3.21%
GOVERNMENT PENSION FUND GLOBALFPI2.96%
TATA AIA LIFE INSURANCE CO LTD-GROWTH ENABLER FUND-ULIF 015 17/10/07 TGE 110Insurance2.71%
AMAL PARIKHIndividual1.93%

Every promoter-group member, and each public holder above 1%, as filed.

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.

Dividends

since 21 Jun 2024 CSV
Financial yearPaymentsDeclaredAdjusted
FY2026-271₹7.55₹3.77
FY2025-261₹10.70₹5.35
FY2024-251₹8.75₹4.38
Ex-dateRecord dateDeclaredAdjusted
24 Jul 2026—₹7.55₹3.77
3 Sept 2025—₹10.70₹5.35
21 Jun 2024—₹8.75₹4.38

Rupees per share by ex-date, from NSE’s corporate actions; the record date is who was paid. Declared is the figure in the filing; adjusted restates it for splits and bonuses since, on the same basis as the price chart. Financial years run April to March.

52-week highs & lows

Loading…

Each session the stock traded past its previous 52-week high or low, from NSE's daily report; the previous figure is the record it broke. Prices as published, not split-adjusted.

Book closures & record dates

Loading…

NSE's corporate-action calendar: who held the stock on the record date, or through the book-closure window, was entitled to the dividend, bonus, split or rights named.

Insider trades

Insiders net, 30d
₹0
Insiders net, 90d
₹0
Promoters net, 90d
₹0
Insider buyers, 90d
0
Last promoter buy
none on record
Disclosures on record
11
10 open-market of the newest 11
By year
BroadcastPersonSideSharesValuePriceHolding before → afterStakeRegulation
23 Sept 2024Chandrashekhar Mukundrao ChawanOtherSell1.0K₹21.1L2,109.4010.0K → 9.0K0.01%-0.00 pp7(2)told 23 Sept 2024
23 Sept 2024Prakash Lalchand SajnaniOtherSell5.0K₹1.1Cr2,168.8022.0K → 17.0K0.02%-0.01 pp7(2)told 23 Sept 2024
4 Sept 2024Devang BhattOtherSell3.0K₹52.0L1,734.7911.1K → 8.1K0.01%-0.00 pp7(2)told 2 Sept 2024
13 Jun 2024Kanishka KapoorRelativeSell10.0K~₹1.4Cr1,431.5010.0K → —0.00%7(2)told 13 Jun 2024
27 Feb 2024Rajendra ModiOtherSell4.0K₹60.0L1,499.5222.0K → 18.0K0.02%-0.00 pp7(2)told 27 Feb 2024
27 Feb 2024Raksha ModiRelativeSell2.0K₹29.8L1,492.3720.0K → 18.0K0.02%-0.00 pp7(2)told 27 Feb 2024
24 Feb 2024Raksha ModiRelativeSell2.0K₹29.3L1,466.5222.0K → 20.0K0.02%-0.00 pp7(2)told 24 Feb 2024
24 Feb 2024Mr. Chandrashekhar Mukundrao ChawanOtherSell1.0K₹14.4L1,444.9011.0K → 10.0K0.01%-0.00 pp7(2)told 24 Feb 2024
22 Nov 2023UTPAL SHETHOtherBuy253₹3.1L1,231.021.5K → 1.7K0.00%0.00 pp7(2)told 22 Nov 2023
21 Nov 2023UTPAL SHETHOtherBuy1.5K₹19.4L1,319.81— → 1.5K0.00%7(2)told 20 Nov 2023

SEBI insider-trading disclosures, equity only. Dated by the day NSE broadcast them; the trade itself is often weeks earlier. The figures count promoters, directors and KMPs buying or selling on the exchange — not ESOPs, gifts, transfers within the promoter group or pledges. Stake is the holding after, as filed; the change beneath it scales that by the share counts before and after. Regulation is the PIT clause cited, and “told” the day the insider informed the company.

How the insider figures are countedPromoters buying in the open market, market-wideEvery stock on this session

Bulk & block deals · 25 Feb 2026

CSV
12 of 12 deals
By year
DateDealClientQuantityPriceValue
25 Feb 2026Sell · bulkNK SECURITIES RESEARCH PRIVATE LIMITED6.17L1,218.58₹75.2Cr
25 Feb 2026Buy · bulkNK SECURITIES RESEARCH PRIVATE LIMITED6.17L1,217.94₹75.1Cr
20 Sept 2024Sell · bulkUBS PRINCIPAL CAPITAL ASIA LIMITED7.40L2,589.86₹191.7Cr
20 Sept 2024Buy · bulkTHE VANGUARD GROUP INC A/C VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND6.98L2,596.08₹181.2Cr
20 Sept 2024Buy · bulkTHE VANGUARD GROUP INC A/C VANGUARD EMERGING MARKETS STOCK INDEX FUND A SERIES OF VANGUARD INTERNAT5.77L2,596.08₹149.8Cr
28 May 2024Sell · bulk1575773 ONTARIO INC35.48L1,361.26₹483.0Cr
28 May 2024Buy · bulkNORGES BANK ON ACCOUNT OF THE GOVERNMENT PENSION FUND GLOBAL6.00L1,386.95₹83.2Cr
18 Aug 2023Sell · bulkNK SECURITIES RESEARCH PRIVATE LIMITED11.32L930.55₹105.3Cr
18 Aug 2023Buy · bulkNK SECURITIES RESEARCH PRIVATE LIMITED11.32L930.12₹105.3Cr
18 Aug 2023Buy · bulkNORGES BANK ON ACCOUNT OF THE GOVERNMENT PENSION FUND GLOBAL8.99L900.05₹80.9Cr
18 Aug 2023Sell · bulkGRAVITON RESEARCH CAPITAL LLP7.35L935.55₹68.8Cr
18 Aug 2023Buy · bulkGRAVITON RESEARCH CAPITAL LLP7.35L935.17₹68.8Cr

A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.

Every stock on this session →

Takeover-code disclosures

Loading…

Filed under SEBI’s takeover regulations when a holding crosses 5% of the company, and again with every 2% it moves after that. Shares and percentages as filed.

Every stock on this session →

Short selling, lending & margin

Loading…

Shares sold short on the day, as brokers reported them to NSE at the close. As reported, not split-adjusted.

Exchange surveillance

20 Nov 2026

No surveillance measure applies to CONCORDBIO.

Price band: 20% · not in the F&O ban.

From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures · band changes.

Every stock on this session →

Financials · quarterly statement

₹ crore, as filed
By year
 Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27Q2 FY27
Revenue from operations240.8319.0215.8310.2244.2429.9204.0247.1277.8326.1257.5309.1
Other income8.210.810.310.014.79.413.713.410.015.312.810.2
Total income249.0329.8226.1320.2258.9439.3217.7260.4287.7341.4270.3319.2
Total expenses148.9198.9147.9186.9159.6254.2160.4177.0197.6227.2193.2223.1
└ Finance costs0.50.50.20.10.10.10.10.10.10.10.00.0
└ Depreciation13.513.713.213.313.314.617.818.418.719.518.118.4
Profit before tax100.1130.978.2133.399.3185.157.283.486.9114.377.196.1
Tax expense25.533.719.934.625.243.214.722.622.525.620.625.9
Net profit77.695.059.695.775.9140.444.163.163.688.557.769.6
EPS3.714.542.854.583.636.712.103.023.044.232.763.33
Net margin32.22%29.79%27.61%30.87%31.09%32.66%21.60%25.53%22.91%27.13%22.41%22.51%
PBT margin41.56%41.04%36.22%42.97%40.67%43.06%28.06%33.75%31.27%35.04%29.93%31.11%
Tax rate25.51%25.74%25.49%25.95%25.40%23.32%25.64%27.13%25.92%22.41%26.79%26.95%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 27 Oct 2026.

Balance sheet & cash flow · half-yearly

₹ crore, as filed
By year

Balance sheet

 H1 FY24FY24H1 FY25FY25H1 FY26FY26H1 FY27
Total assets1,551.01,700.71,764.32,034.32,023.22,234.72,327.0
Current assets755.6896.2934.71,135.21,079.81,250.11,290.7
└ Cash & equivalents6.115.17.40.917.312.27.5
└ Other bank balances68.831.91.10.31.81.40.1
└ Current investments150.2243.7275.3316.5312.3402.1438.1
└ Trade receivables267.0349.6344.4521.7396.8460.2412.5
└ Inventories219.9208.0250.4239.7276.3326.4397.8
Total equity1,354.31,526.61,590.41,812.71,826.82,015.12,071.9
└ Attributable to owners1,354.31,526.61,590.41,812.71,827.52,017.12,075.8
└ Non-controlling interest0.0—0.00.0(0.7)(1.9)(3.9)
└ Share capital10.510.510.510.510.510.510.5
Borrowings18.76.20.00.40.00.00.0
└ Current18.76.20.00.40.00.00.0
└ Non-current0.00.00.00.00.00.00.0
Trade payables76.194.482.2113.086.6101.9112.1
Current liabilities167.4142.2141.7184.1155.0169.1201.7
Total liabilities196.7174.1174.0221.5196.4219.6255.1
Net debt(206.3)(284.5)(283.7)(317.3)(331.4)(415.6)(445.8)
Debt / equity0.010.000.000.000.000.000.00
Current ratio4.516.306.606.176.977.396.40

Cash flow, year to date

 H1 FY24FY24H1 FY25FY25H1 FY26FY26H1 FY27
Operating cash flow117.1265.5151.1244.5151.1266.9168.2
└ Capex(29.9)(85.7)(49.8)(111.2)(53.5)(95.2)(60.0)
Free cash flow87.2179.8101.3133.397.6171.7108.2
Investing cash flow(28.7)(154.6)(59.7)(160.0)(21.3)(142.7)(93.3)
Financing cash flow(85.8)(99.2)(99.1)(98.8)(113.4)(112.9)(79.6)
└ Dividends paid(71.5)(71.5)(91.5)(91.5)(111.9)(111.9)(79.0)
└ Buybacks0.00.00.00.00.00.00.0
Net change in cash2.611.6(7.7)(14.2)16.411.3(4.7)

From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.

Announcements & board meetings

Loading…

As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.

Every stock on this session →

CONCORDBIO at a glance

  • CONCORDBIO closed at ₹548.2 on 20 Nov 2026, -1.47% on the day, -26.9% over one year, 32.1% below its 52-week high of ₹807.5.
  • Delivery was 57.4% of traded quantity on 20 Nov 2026, the 78th percentile of its own 809 sessions with a reading (20-session average 44.5%, 1-year average 46.1%).
  • Market capitalisation is ₹11,470 crore at a trailing P/E of 40.6 (trailing EPS ₹13.5).
  • Q2 FY27 results (consolidated, filed 27 Oct 2026): revenue ₹309 crore (+25.1% year on year), net profit ₹70 crore (+10.3%); the price moved -7.8% on the first session after.
  • Promoters held 44.09% at 5 Nov 2026, unchanged on the previous filing.
  • Q3 FY27 results are expected between 9 Feb 2027 and 14 Feb 2027, going by past filing dates — an estimate, not an announcement.

About

Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE338H01029
SeriesEQ
Listed18 Aug 2023
IPO price741.00 · band Rs.705 to Rs.741
IPO listing18 Aug 2023
NSE market cap · 17 Nov 2026₹11,608 Cr
Free-float market cap (NSE)₹3,657 Cr
Shares outstanding (NSE)20.92Cr
History from18 Aug 2023
Sessions809
Turnover rank#679

Sector history

  1. to 16 Aug 2026Index industry · Healthcare
  2. from 16 Aug 2026Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

NSE’s own classification, by the snapshot it changed on.

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.